Compare Salesforce Inc (CRM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Viatris Inc — how do they compare? Salesforce Inc trades at $168.08 (market cap $137.23B), while Viatris Inc trades at $16.45 (market cap $18.99B). The key difference: Salesforce Inc is far larger — about 7.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.94%). Which is the better fit depends on your goals.
| CRM | VTRS | |
|---|---|---|
Market Cap | $137.23B | $18.99B |
Sector | Technology | Health |
52-Week High | $270.25 | $17.39 |
52-Week Low | $150.12 | $8.74 |
Enterprise Value | $167.28B | $31.20B |
Dividend Yield | 1.05% | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $168.75, down 1.44% on the day amid a broader tech sell-off. The stock exhibits a neutral technical signal with support near $165 and resistance at $171. Fundamentally, the company shows strong profitability with a 77.64% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven growth potential but also reflects market concerns over software stock volatility.
The outlook remains positive given robust earnings beats, high analyst buy ratings (76.84%), and a consensus price target of $235.90, implying significant upside. Key risks include competitive pressures in AI, macroeconomic sensitivity, and the stock's high valuation multiples. Revenue growth and AI monetization are critical catalysts for future performance.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
